- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06646991
Comparison of Several Oxygenation Targets With Different Oxygen Interfaces - Impact on Oxygen Flow Rates (Interfaces)
Oxygen therapy is at the heart of the healthcare system. Oxygen flow rates depend on a number of confounding factors confounding factors (target used, skin pigmentation, pulse oximeter used, etc.) The investigators have recently have recently demonstrated that the combination of these factors (different peripheral oxygen saturation (SpO2) targets and different oximeters) can have a significant impact on oxygen flows rates. The effect on oxygen flow was not simply additive .
The aim of this study is to evaluate the impact of the interface used on oxygen flow rates in different patient populations (main objective). The investigatoers also evaluate the impact of the interface on carbon dioxide (PaCO2), in particular with closed oxygen masks, with which rebreathing is theoretically possible (secondary objective).
secondary objective).
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: François Lellouche
- Phone Number: 1-418-656-8711
- Email: françoislellouche@criucpq.ulaval.ca
Study Locations
-
-
-
Quebec, Canada, G1V4G5
- Institut Universitaire de Cardiologie et de Pneumologie de Quebec
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult (> or = 18 years old)
- Ongoing on conventional oxygen therapy with peripheral oxygen saturation (SpO2) between 88 and 100% with the usual oximeter
- SpO2 < 92% ambient air with the usual oximeter
Exclusion Criteria:
- No SpO2 signal with with the usual oximeter
- False nails or nail polish
- Severe anemia documented on last blood count during current hospitalization (haemoglobin (Hb) < 80g/L)
- Oxygen flow > 6 L/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Nellcor oximeter
|
Oxygen will be administered via nasal cannula up to 6 liters per minute during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used. Oxygen will be administered via nasal cannula up to 15 liters per minute during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used. Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used. Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used. |
|
Other: Nonin Oximeter
|
Oxygen will be administered via nasal cannula up to 6 liters per minute during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient). The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygen flow
Time Frame: Mean Oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
Oxygen flows (or fraction of inspired oxygen (FiO2)) at the end of each study period (last minute average) to reach peripheral oxygen saturation (SpO2) target to reach SpO2 target with specific oxygen administration interfaces
|
Mean Oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Partial oxygen weaning
Time Frame: Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
Rate of partial oxygen weaning (Oxygen flow <=0.5 L/min)
|
Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
|
Complete oxygen weaning
Time Frame: Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
Rate of complete oxygen weaning (Oxygen flow =0 L/min or FiO2 0.21)
|
Mean oxygen flow in the five last minute of each study period (between minute 10 and 15)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gaps between the different oximeters
Time Frame: through period completion, minute 15
|
Average of the SpO2 value gaps between the different oximeters tested
|
through period completion, minute 15
|
|
Gaps between PaCO2
Time Frame: through period completion, minute 15
|
PaCO2 value at the end of the period
|
through period completion, minute 15
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-4198
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Hemovent GmbHseleon GmbHRecruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory Failure | Imminent Cardiorespiratory or Respiratory FailureGermany
-
University Hospital, Strasbourg, FranceRecruitingRespiratory Failure | Cardiac FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
University of OsloOslo University HospitalCompletedHypercapnic Respiratory Failure | Type 2 Respiratory FailureNorway
-
Fisher and Paykel HealthcareCentre hospitalier de l'Université de Montréal (CHUM); Institut universitaire...RecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureCanada
-
Siriraj HospitalCompletedAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
-
Hospital Sao JoaoCompletedVentilatory Failure | Post-extubation Failure | Persistent Weaning Failure | Secretion Encumbrance | Weak CoughPortugal
Clinical Trials on Nasal canula - up to 6 liters per minute
-
University of ArkansasTerminatedBronchopulmonary DysplasiaUnited States
-
Noah GreenspanUniversity of DaytonRecruiting
-
University of JaénNot yet recruitingHealthy Adult Male and Female VolunteersSpain
-
Assistance Publique - Hôpitaux de ParisAction Research GroupTerminatedDepression | Coronary Artery DiseaseFrance
-
Weill Medical College of Cornell UniversityBoehringer IngelheimCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedCancer | Malignant NeoplasmUnited States
-
Tanta UniversityRecruitingEndodontic Disease | Irrigation ActivationEgypt